Summary
Pafenolol, a new selective adrenergic beta1-blocking agent, has been tested for the first time in 6 hypertensive patients. After single oral doses of pafenolol 25 to 100 mg, there was a marked reduction in heart rate and systolic blood pressure during exercise tests. These effects were dose dependent. A significant positive correlation was found between the reduction in heart rate during exercise and the plasma level of pafenolol 5 hours after drug intake (correlation coefficient r=0.94). Side effects were mild and seemed to be dose dependent. It is concluded that this new beta1-blocking agent was effective in reducing blood pressure and was well tolerated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bengtsson C, Johnsson G, Regårdh C-G (1975) Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment. Clin Pharmacol Ther 17: 400–408
Bjurö TI, Falk K-J, Angelhed J-E (1980) The isopotential plot — a new method for the assessment of ST amplitude changes provoked by an exercise test. Eur Heart J 1: 213–223
Björkman J-A, Ek L, Carlsson E, Lundgren B (1982) Pafenolol, II. Cardiovascular effects in anaesthetized dogs. Abstract. XVII Scandinavian Congress for Physiology and Pharmacology. 29–31 Aug, 1982, Reykjavik. Acta Physiol Scand [Suppl 508]: 42
Ek L, Carlsson E, Hoffman KJ, Lundgren B, Skånberg I (1982) Pafenolol, III. Blockade of exercise tachycardia and duration of action in the conscious dog. Abstract. XVII Scandinavian Congress for Physiology and Pharmacology. 29–31 Aug, 1982, Reykjavik. Acta Physiol Scand [Suppl 508]: 42
Hossmann V, Fitzgerald GA, Dollery CT (1981) Influence of hospitalization and placebo therapy on blood pressure and sympathetic function in essential hypertension. Hypertension 3: 113–118
Johnsson G, Regårdh C-G, Sölvell L (1975) Combined pharmacokinetic and pharmacodynamic studies in man of the adrenergic beta1-receptor antagonist metoprolol. Acta Pharmacol Toxicol [Suppl 5] 36: 31–44
Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG Jr (1967a) Differentiation of receptor systems activated by sympathomimetic amines. Nature 214: 597–598
Lands AM, Luduena FP, Buzzo HJ (1967b) Differentiation of receptors responsive to isoproterenol. Life Sci 6: 2241–2249
Löfdahl C-G, Marlin GE, Svedmyr N (1983) Pafenolol, a highly selective β1-adrenoceptor-antagonist, in asthmatic patients: interaction with terbutaline. Clin Pharmacol Ther 33: 1–9
Lundgren B, Carlsson E, Ek L (1982) Pafenolol. 1. Betablocking potency and selectivity in in vivo and in vitro experiments. Abstract. XVII Scandinavian Congress for Physiology and Pharmacology. 29–31 Aug. 1982, Reykjavik. Acta Physiol Scand [Suppl 508]: 44
Report of a WHO Expert Committee (1978) Arterial hypertension. WHO Tech Rep Ser No 628
Wikstrand J, Berglund G, Wilhelmsen L, Wallentin I (1976) Orthogonal electrocardiogram, apex cardiogram, and atrial sound in normotensive and hypertensive 50-year-old men. Br Heart J 38: 779–789
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sigurdsson, J.A., Bengtsson, C. & Bjurö, T. Pafenolol, a new β1-selective blocking agent, in mild hypertension. Result of an inpatient study and a subsequent outpatient follow-up. Eur J Clin Pharmacol 26, 549–553 (1984). https://doi.org/10.1007/BF00543483
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00543483